These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 29938343)

  • 1. Interrogation of a longitudinal, national pharmacy claims dataset to explore factors that predict the need for add-on therapy in older and socioeconomically disadvantaged Australians with type 2 diabetes mellitus patients (T2DM).
    Kumar SS; McManus H; Radovich T; Greenfield JR; Viardot A; Williams KM; Cronin P; Day RO
    Eur J Clin Pharmacol; 2018 Oct; 74(10):1327-1332. PubMed ID: 29938343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy.
    Inzucchi SE; Tunceli K; Qiu Y; Rajpathak S; Brodovicz KG; Engel SS; Mavros P; Radican L; Brudi P; Li Z; Fan CP; Hanna B; Tang J; Blonde L
    Diabetes Obes Metab; 2015 Oct; 17(10):956-64. PubMed ID: 25962401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
    Bergeson JG; Worley K; Louder A; Ward M; Graham J
    J Manag Care Pharm; 2013 Jun; 19(5):374-84. PubMed ID: 23697475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Historical cohort analysis of treatment patterns for patients with type 2 diabetes initiating metformin monotherapy.
    Hazel-Fernandez L; Xu Y; Moretz C; Meah Y; Baltz J; Lian J; Kimball E; Bouchard J
    Curr Med Res Opin; 2015; 31(9):1703-16. PubMed ID: 26154837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association between adherence to oral anti-diabetic drugs and hypoglycaemia in persons with Type 2 diabetes.
    Quilliam BJ; Ozbay AB; Sill BE; Kogut SJ
    Diabet Med; 2013 Nov; 30(11):1305-13. PubMed ID: 23586474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
    Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
    Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased risk of affective disorders in type 2 diabetes is minimized by sulfonylurea and metformin combination: a population-based cohort study.
    Wahlqvist ML; Lee MS; Chuang SY; Hsu CC; Tsai HN; Yu SH; Chang HY
    BMC Med; 2012 Nov; 10():150. PubMed ID: 23194378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of adherence and weight loss on glycemic control in patients with type 2 diabetes: cohort analyses of integrated medical record, pharmacy claims, and patient-reported data.
    McAdam-Marx C; Bellows BK; Unni S; Wygant G; Mukherjee J; Ye X; Brixner DI
    J Manag Care Spec Pharm; 2014 Jul; 20(7):691-700. PubMed ID: 24967522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regional variation in medication-taking behaviour of new users of oral anti-hyperglycaemic therapy in Ireland.
    O'Shea MP; Teeling M; Bennett K
    Ir J Med Sci; 2015 Jun; 184(2):403-10. PubMed ID: 24859371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient and prescriber characteristics among patients with type 2 diabetes mellitus continuing or discontinuing sulfonylureas following insulin initiation: data from a large commercial database.
    Beachler DC; Fernandes G; Deshpande G; Jemison J; Lyons JG; Lanes S; Liu J; McNeill A
    Curr Med Res Opin; 2018 Jun; 34(6):1061-1069. PubMed ID: 29264933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis.
    Vanderpoel DR; Hussein MA; Watson-Heidari T; Perry A
    Clin Ther; 2004 Dec; 26(12):2066-75. PubMed ID: 15823770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does antidepressant medication use affect persistence with diabetes medicines?
    Caughey GE; Preiss AK; Vitry AI; Gilbert AL; Ryan P; Shakib S; Esterman A; McDermott RA; Roughead EE
    Pharmacoepidemiol Drug Saf; 2013 Jun; 22(6):615-22. PubMed ID: 23447430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological treatment initiation for type 2 diabetes in Australia: are the guidelines being followed?
    Wood SJ; Magliano DJ; Bell JS; Shaw JE; Keen CS; Ilomäki J
    Diabet Med; 2020 Aug; 37(8):1367-1373. PubMed ID: 31557346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug usage patterns and treatment costs in newly-diagnosed type 2 diabetes mellitus cases, 2007 vs 2012: findings from a large US healthcare claims database analysis.
    Weng W; Liang Y; Kimball ES; Hobbs T; Kong S; Sakurada B; Bouchard J
    J Med Econ; 2016 Jul; 19(7):655-62. PubMed ID: 26855139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial therapy, persistence and regimen change in a cohort of newly treated type 2 diabetes patients.
    Grimes RT; Bennett K; Tilson L; Usher C; Smith SM; Henman MC
    Br J Clin Pharmacol; 2015 Jun; 79(6):1000-9. PubMed ID: 25521800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescribing for people with type 2 diabetes and renal impairment in Australian general practice: A national cross sectional study.
    Manski-Nankervis JE; Thuraisingam S; Sluggett JK; Lau P; Blackberry I; Ilomaki J; Furler J; Bell JS
    Prim Care Diabetes; 2019 Apr; 13(2):113-121. PubMed ID: 30262176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression to insulin for patients with diabetes mellitus on dual oral antidiabetic therapy using the US Department of Defense Database.
    Rascati K; Richards K; Lopez D; Cheng LI; Wilson J
    Diabetes Obes Metab; 2013 Oct; 15(10):901-5. PubMed ID: 23531154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 2 Diabetes Mellitus Treatment Patterns Across Europe: A Population-based Multi-database Study.
    Overbeek JA; Heintjes EM; Prieto-Alhambra D; Blin P; Lassalle R; Hall GC; Lapi F; Bianchini E; Hammar N; Bezemer ID; Herings RMC
    Clin Ther; 2017 Apr; 39(4):759-770. PubMed ID: 28342563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence and ingredient cost of chronic comorbidity in the Irish elderly population with medication treated type 2 diabetes: a retrospective cross-sectional study using a national pharmacy claims database.
    O'Shea M; Teeling M; Bennett K
    BMC Health Serv Res; 2013 Jan; 13():23. PubMed ID: 23324517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.